

**Background:** F901318 is the most advanced candidate from a novel series of antifungal agents, the orotomides. F901318 is currently being developed for the treatment of serious systemic fungal infections, in particular invasive aspergillosis. In this study the potency of F901318 was compared with established antifungal agents against a large panel of clinical *Aspergillus* isolates from the UK and the Tyrol region of Austria. **Methods:** A total of 221 *Aspergillus* strains (*A. fumigatus* n= 80, *A. terreus* n = 45, *A. flavus* n=50 and *A. niger* n=46) were tested for susceptibility to F901318. The testing methods used are as outlined in CLSI document M38-A2. All organisms were tested in the microdilution format. Voriconazole, posaconazole, itraconazole and amphotericin B were tested as comparators. In an inhaled model of aspergillosis

0 2160 1512 reTf1 0 0 1 580.37 1047.7 Tm0 g7 Tm0 g0 G[ )TJET0 0 2160 1512 reW^nBT/F3 14.04 Tf1n4 14.04 Tf1 0 0 1 574.61.7 T[a]9(m) nBT/F3 14.04 Tf1 0 0 1 423.86 1047.7 Tm0 g0 G[ )TJET9/F3 14.04 Tf1 0 0 1 574.1 0 0 1 580